Carvedilol update III: Rationale for use in congestive heart failure

G. Z. Feuerstein, G. Poste, R. R. Ruffolo

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


In February of 1995, several multicenter, double-blind, placebo-controlled clinical trials of the novel, multiple action cardiovascular drug, carvedilol, were terminated prematurely for ethical reasons due to the remarkable reduction in mortality observed in patients receiving carvedilol plus conventional therapy (i.e., angiotensin converting enzyme inhibitors, diuretics and digitalis) compared to patients receiving placebo plus conventional therapy. The dramatic reduction in mortality produced by carvedilol occurred across all studies and was observed in patients with mild, moderate and severe heart failure. The results of these dramatic clinical trials with carvedilol will be presented later this year.

Original languageEnglish (US)
Pages (from-to)307-326
Number of pages20
JournalDrugs of Today
Issue number5
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Carvedilol update III: Rationale for use in congestive heart failure'. Together they form a unique fingerprint.

Cite this